Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
نویسندگان
چکیده
منابع مشابه
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
New anticoagulants, like the orally available direct thrombin inhibitor (DTI) dabigatran etexilate, have recently been introduced into the market for venous thromboembolic prophylaxis and for stroke prevention in atrial fibrillation. While dabigatran has been approved for use without the need for routine therapeutic monitoring, there are clinical scenarios in which monitoring can help guide cli...
متن کاملDabigatran etexilate: a new thrombin inhibitor.
Dabigatran etexilate was recently approved by the Therapeutic Goods Administration for thromboprophylactic use in adults undergoing elective total hip or knee replacement. Dabigatran etexilate is the prodrug of the active moiety dabigatran, an orally active agent that could replace enoxaparin in some clinical indications. Dabigatran is a direct thrombin inhibitor; it has stable, predictable pha...
متن کاملThrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice
INTRODUCTION Atherosclerosis is a chronic inflammatory disease characterized by endothelial cell damage, infiltration, proliferation and accumulation of macrophages, lymphocytes and transformed vascular smooth muscle cells within the vascular wall and procoagulation processes involving activation of plasmatic coagulation events and platelets. Numerous studies suggested a close interaction betwe...
متن کاملDRUG EVALUATION Dabigatran etexilate: an oral direct thrombin inhibitor
10.2217/14750708.5.5.685 © 2 Dabigatran etexilate is a direct thrombin inhibitor that offers potential advantages over existing anticoagulants for the prevention and treatment of venous and arterial thrombosis. It is administered orally, has a rapid onset of action, a predictable anticoagulant effect and does not require laboratory monitoring. Trial results indicate that dabigatran etexilate ha...
متن کاملDabigatran (Rendix): A Promising New Oral Direct Thrombin Inhibitor
INTRODUCTION Thromboembolic events are significant sources of morbidity and mortality that often necessitate long-term anticoagulation therapy. Although a variety of effective anticoagulants exist, heparins, heparinoids, and most direct thrombin inhibitors are available as injectable formulations and are typically unsuitable for long-term use. Warfarin (Coumadin, Bristol-Myers Squibb), an oral ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Applied Thrombosis/Hemostasis
سال: 2019
ISSN: 1076-0296,1938-2723
DOI: 10.1177/1076029619867137